---
schema_version: "secwatch.filing_event.v1"
accession: "0001794546-26-000010"
form_type: "8-K"
ticker: "CARL"
cik: "0001794546"
company_name: "CARLSMED, INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:30:02.186059+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Carlsmed Q1 revenue $16.1M (+58% YoY); raises FY2026 guidance to $72-77M

## Summary
- Revenue $16.1M, up 58% YoY from $10.2M; gross margin 77.1% vs 74.9%.
- Net loss ($8.7M) vs ($5.7M); adjusted EBITDA ($7.5M) vs ($5.5M).
- FY2026 revenue guidance raised to $72-$77M from prior $70-$75M.
- Study in Global Spine Journal shows 74% reduction in reoperations with aprevo implants.
- First procedures completed with corra cervical plating system and aprevo bi-lateral posterior in Feb.

## SEC filing metadata
- accession: 0001794546-26-000010
- form_type: 8-K
- ticker: CARL
- cik: 0001794546
- company_name: CARLSMED, INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1794546/000179454626000010/0001794546-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1794546/000179454626000010/carl-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001794546-26-000010
- JSON: https://secwatch.observer/filing/0001794546-26-000010.json
- Plain text: https://secwatch.observer/filing/0001794546-26-000010.txt

## Key facts
- Earnings Releases
  CARLSMED, INC. reported first quarter ended March 31, 2026 results: revenue $16.1 million, net income ($8.7) million. Guidance raised.
  - Period: first quarter ended March 31, 2026
  - Revenue: $16.1 million
  - Net income: ($8.7) million
  - Guidance: raised
  - Result: reported results
  source text: set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Carlsmed ® Reports First Quarter 2026 Financial Results First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, CALIFORNIA, MAY 5, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1794546/000179454626000010/0001794546-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.